GVS assessment ponesimod (Ponvory®) for the treatment of relapsing forms of multiple sclerosis (RMS)

National Health Care Institute has completed its assessment whether ponesimod (Ponvory®) can be included in the Medication Reimbursement System (GVS). Ponesimod is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease. The National Health Care Institute's advice is to include ponesimod on List 1A of the GVS in cluster 0N07XXCO V.

Registered indication

Ponesimod is available as a film-coated tablet in various doses ranging from 2 mg to 20 mg and is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

National Health Care Institute's advice

Based on the criteria for interchangeability, it can be concluded that ponesimod (Ponvory®) is interchangeable with the other medicinal products in the GVS cluster 0N07XXCO V, which includes: ozanimod (Zeposia®), teriflunomide (Aubagio®) and dimethyl fumarate (Tecfidera®).

The National Health Care Institute's therefore advises the Minister to include ponesimod on List 1A in cluster 0N07XXCO V of the GVS. The standard dose for ponesimod can be set at 20 mg.

This report is a summary of recommendations by National Health Care Institute. The original text is in Dutch.